// App-Quantinova.ai

: Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial

Researchers

Presenter

  • Jaclyn Smith

Principal Investigators

  • Elizabeth Ballantyne

  • Mary Kerr

  • Lorcan Mcgarvey

  • Alyn Morice

  • Mandel Sher

  • Michael Trower

  • Stephen Pawsey

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • Freeline Therapeutics, Stevenage, United Kingdom

  • Queen's University Belfast, Belfast, United Kingdom

  • The Hull York Medical School, Cottingham, United Kingdom

  • Center for Cough, Largo, Largo, FL, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Orvepitant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

  • Parallel Group

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved